Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 88, Issue 1, Pages 130-134Publisher
WILEY
DOI: 10.1038/clpt.2010.95
Keywords
-
Categories
Funding
- European Commission [DG-INFSO-224381]
- Virtual Physiological Human Network of Excellence
- MRC [G0700278] Funding Source: UKRI
- Medical Research Council [G0700278] Funding Source: researchfish
Ask authors/readers for more resources
Side effects account for most of the instances of failure of candidate drugs at late stages of development. These development failures contribute to the exorbitant cost of bringing new compounds to market: a single withdrawal can represent a loss of more than $1 billion. Many unwanted actions of drugs affect the heart, resulting in potentially proarrhythmic alteration of ion channel function. Because these can be fatal, potential electrophysiological cardiotoxicity is among the most stringent exclusion criteria in the licensing process.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available